The incidence of prostate cancer varies by rates of prostate-specific antigen (PSA) screening and national guidelines, but cases of prostate cancer worldwide are projected to approach 3 million per year by 2040 (James et al. 2024). This evidence concerns the gene KLK3 and prostate cancer.